230 related articles for article (PubMed ID: 33334714)
1. Impact of biofilm formation and azoles' susceptibility in Scedosporium/Lomentospora species using an in vitro model that mimics the cystic fibrosis patients' airway environment.
Mello TP; Lackner M; Branquinha MH; Santos ALS
J Cyst Fibros; 2021 Mar; 20(2):303-309. PubMed ID: 33334714
[TBL] [Abstract][Full Text] [Related]
2. Decoding the antifungal resistance mechanisms in biofilms of emerging, ubiquitous and multidrug-resistant species belonging to the Scedosporium/Lomentospora genera.
Mello TP; Oliveira SSC; Branquinha MH; Santos ALS
Med Mycol; 2022 Jun; 60(6):. PubMed ID: 35641191
[TBL] [Abstract][Full Text] [Related]
3. Cell dispersion during biofilm formation by
Mello TP; Barcellos IC; Branquinha MH; Santos ALS
Curr Res Microb Sci; 2023; 4():100191. PubMed ID: 37229517
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium.
Sedlacek L; Graf B; Schwarz C; Albert F; Peter S; Würstl B; Wagner S; Klotz M; Becker A; Haase G; Laniado G; Kahl B; Suerbaum S; Seibold M; Tintelnot K
J Cyst Fibros; 2015 Mar; 14(2):237-41. PubMed ID: 25595044
[TBL] [Abstract][Full Text] [Related]
5. Conidial germination in Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans: influence of growth conditions and antifungal susceptibility profiles.
Mello TP; Aor AC; Oliveira SS; Branquinha MH; Santos AL
Mem Inst Oswaldo Cruz; 2016 Jun; 0(7):0. PubMed ID: 27355215
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility patterns for Aspergillus, Scedosporium, and Exophiala isolates recovered from cystic fibrosis patients against amphotericin B, and three triazoles and their impact after long-term therapies.
Brito Devoto T; Hermida-Alva K; Posse G; Finquelievich JL; García-Effrón G; Cuestas ML
Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37591630
[TBL] [Abstract][Full Text] [Related]
7. Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans.
Kirchhoff L; Dittmer S; Weisner AK; Buer J; Rath PM; Steinmann J
J Antimicrob Chemother; 2020 Aug; 75(8):2133-2140. PubMed ID: 32386411
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
9. Peptidorhamnomannans From
de Oliveira EB; Xisto MIDDS; Rollin-Pinheiro R; Rochetti VP; Barreto-Bergter E
Front Cell Infect Microbiol; 2020; 10():598823. PubMed ID: 33251161
[No Abstract] [Full Text] [Related]
10. The synergistic effect of minocycline and azole antifungal drugs against Scedosporium and Lomentospora species.
Yang F; Sun Y; Lu Q
BMC Microbiol; 2022 Jan; 22(1):21. PubMed ID: 35016611
[TBL] [Abstract][Full Text] [Related]
11. Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis.
Schwarz C; Brandt C; Melichar V; Runge C; Heuer E; Sahly H; Schebek M; Köster H; Bouchara JP; Biedermann T; Meißner P; Große-Onnebrink J; Skopnik H; Hartl D; Sedlacek L; Tintelnot K
J Cyst Fibros; 2019 Mar; 18(2):227-232. PubMed ID: 30297214
[TBL] [Abstract][Full Text] [Related]
12. Active Cu(II), Mn(II) and Ag(I) 1,10-phenanthroline/1,10-phenanthroline-5,6-dione/dicarboxylate chelates: effects on
Mello TP; Aor AC; Barcellos IC; Pereira MM; McCann M; Devereux M; Branquinha MH; Santos AL
Future Microbiol; 2023 Nov; 18():1049-1059. PubMed ID: 37284767
[TBL] [Abstract][Full Text] [Related]
13. Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.
Wu Y; Grossman N; Totten M; Memon W; Fitzgerald A; Ying C; Zhang SX
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816726
[No Abstract] [Full Text] [Related]
14. Fungal epidemiology in cystic fibrosis patients with a special focus on Scedosporium species complex.
Hedayati MT; Tavakoli M; Maleki M; Heidari S; Mortezaee V; Gheisari M; Hassanzad M; Mirenayat MS; Mahdaviani SA; Pourabdollah M; Velayati AA; Vakili M; Abastabar M; Haghani I; Jafarzadeh J; Hedayati N; Seyedmousavi S; Alastruey-Izquierdo A
Microb Pathog; 2019 Apr; 129():168-175. PubMed ID: 30742949
[TBL] [Abstract][Full Text] [Related]
15. Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.
Rollin-Pinheiro R; Xisto MIDDS; de Castro-Almeida Y; Rochetti VP; Borba-Santos LP; Fontes YDS; Ferreira-Pereira A; Rozental S; Barreto-Bergter E
PLoS One; 2023; 18(2):e0280964. PubMed ID: 36735743
[TBL] [Abstract][Full Text] [Related]
16. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.
Wiederhold NP; Law D; Birch M
J Antimicrob Chemother; 2017 Jul; 72(7):1977-1980. PubMed ID: 28333310
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal and Fungicidal Activity of
Gruber M; Moser I; Nagl M; Lackner M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223376
[TBL] [Abstract][Full Text] [Related]
18. Identification of 14-α-Lanosterol Demethylase (CYP51) in Scedosporium Species.
Bernhardt A; Meyer W; Rickerts V; Aebischer T; Tintelnot K
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891611
[No Abstract] [Full Text] [Related]
19. Assessment of biofilm formation by Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans.
Mello TP; Aor AC; Gonçalves DS; Seabra SH; Branquinha MH; Santos AL
Biofouling; 2016 Aug; 32(7):737-49. PubMed ID: 27309801
[TBL] [Abstract][Full Text] [Related]
20.
Furnica DT; Dittmer S; Scharmann U; Meis JF; Steinmann J; Rath PM; Kirchhoff L
Microbiol Spectr; 2023 Jun; 11(3):e0513022. PubMed ID: 37017567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
